Overview
Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of FP187®, a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the recent Settlement and License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on sales of Tecfidera® or other DMF products for MS, dependent on, among other things, successfully appealing the U.S. interference and a favorable outcome in Europe with respect to the EP2801355 Opposition Proceedings, including any appeal thereto.
| Date | Title | | | 02/07/18 | Forward Pharma to Present at the 7th Annual Leerink Partners Global Healthcare Conference| COPENHAGEN, Denmark, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will give a corporate update at the 7th Annual Leerink Partners Global Healthcare Conference in New York, NY. Dr. Svendsen will present on Thursday, February 15, 2018 at 10:30 AM ET and host one-on-one meetings.
Investors and other interested parties may access a live audio webcast of our conference presentati... |
|  | | 01/29/18 | Forward Pharma Announces the Decision of the European Patent Office in the Opposition Proceedings for the EP2801355 Patent| Forward Pharma Expects to Appeal the Decision Upon Review
COPENHAGEN, Denmark, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced that the European Patent Office (the “EPO”) has revoked the EP2801355 patent (the “’355 patent”) following the oral hearing in the Opposition Proceedings.
The EPO Opposition Division revoked the ’355 patent after considering third-party oppositions from several opponents. The Opposition Division will is... |
| | | 12/21/17 | Forward Pharma Files Final Brief in its Appeal of the U.S. Patent Interference to the Federal Circuit| Oral argument expected in second or third quarter of 2018
COPENHAGEN, Denmark, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced the filing of its reply brief to the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) in the appeal of the PTAB’s decision in the interference proceeding between the Forward 11/576,871 patent application (the “’871 application”) and an issued Biogen patent.
The reply brief will beco... |
| | | 11/29/17 | Forward Pharma Files Further Written Submissions in the European Opposition Proceeding for the EP2801355 Patent in Preparation for the Oral Hearing in January 2018| COPENHAGEN, Denmark, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced the filing of further written submissions in the European Opposition Proceeding for the EP2801355 patent (“the ‘355 patent”) with the Opposition Division of the European Patent Office (“EPO”).
“We continue to vigorously defend our intellectual property and have filed strong argumentation to uphold our issued ‘355 patent,” said Dr. Claus Bo Svendsen, CEO of Forw... |
| |
|
 |
| There are currently no events scheduled. |
Receive E-mail Alerts |
| Sign up to receive e-mail alerts whenever Forward Pharma A/S posts new information to the site. Just enter your e-mail address and click Submit. |
